HomeMOLN • NASDAQ
add
Molecular Partners AG
Nakaraang pagsara
$3.75
Sakop ng araw
$3.72 - $3.74
Sakop ng taon
$3.36 - $7.60
Market cap
144.10M USD
Average na Volume
3.66K
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (CHF) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 3.99M | -10.05% |
Net na kita | -20.40M | -35.25% |
Net profit margin | — | — |
Kita sa bawat share | -0.56 | — |
EBITDA | -14.15M | 7.98% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CHF) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 114.49M | -28.05% |
Kabuuang asset | 124.25M | -27.17% |
Kabuuang sagutin | 17.59M | 16.89% |
Kabuuang equity | 106.66M | — |
Natitirang share | 37.39M | — |
Presyo para makapag-book | 1.32 | — |
Return on assets | -27.70% | — |
Return on capital | -30.77% | — |
Cash Flow
Net change in cash
| (CHF) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -20.40M | -35.25% |
Cash mula sa mga operasyon | -13.10M | 16.68% |
Cash mula sa pag-invest | 14.97M | 13.85% |
Cash mula sa financing | -243.00K | 8.99% |
Net change in cash | 603.00K | 122.68% |
Malayang cash flow | -3.61M | 63.16% |
Tungkol
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Itinatag
2004
Website
Mga Empleyado
153
